Background: Regimens that could treat both rifampin-resistant (RR) and rifampin-susceptible tuberculosis (TB)\nwhile shortening the treatment duration have reached late-stage clinical trials. Decisions about whether and how to\nimplement such regimens will require an understanding of their likely clinical impact and how this impact depends\non local epidemiology and implementation strategy.\nMethods: A Markov state-transition model of 100,000 representative South African adults with TB was used to\nsimulate implementation of the regimen BPaMZ (bedaquiline, pretomanid, moxifloxacin, and pyrazinamide), either\nfor RR-TB only or universally for all patients. Patient outcomes, including cure rates, time with active TB, and time on\ntreatment, were compared to outcomes under current care. Sensitivity analyses varied the drug-resistance\nepidemiology, rifampin susceptibility testing practices, and regimen efficacy.\nResults: Using BPaMZ exclusively for RR-TB increased the proportion of all RR-TB that was cured by initial treatment.....................
Loading....